CVS HEALTH Corp (CVS) Factsheet
Earnings-call transcript: covered (issuer-published) · IR deck: cataloged — watch a real agent read these end-to-end →
CVS HEALTH Corp (CVS) Stock Analysis
Analysis from 10-Q filed 2025-10-29. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 5.0%. FCF margin 2.8%. D/E 0.8x. Source: 10-Q filed 2025-10-29.
| Metric | Value | Context |
|---|---|---|
| ROIC | 5.0% | Below expectations |
| FCF Margin | 2.8% | Cash flow pressure |
| Debt/Equity | 0.8x | Moderate leverage |
ROIC 5.0% — Bottom 50% of sector peers. FCF margin 2.8% — Top 50%.
Explore CVS HEALTH Corp: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for CVS: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: CVS HEALTH Corp earns 5.0% ROIC, Bottom 50% in Consumer Discretionary
ROIC TTM 5.0%, sector median 7.1%, Bottom 50%. DuPont: NOPAT margin 1.7% × asset turnover 1.6x. Gross margin 44.5%. Operating margin 2.0%. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.0% | Warning | Below sector median of 7.1% |
| Return on Equity (ROE) | 6.4% | Warning | Moderate equity returns |
| Gross Margin | 44.5% | Good | Strong pricing power |
| Operating Margin | 2.0% | Warning | Moderate operational efficiency |
Cash Flow: CVS HEALTH Corp generates $11.8B FCF at 2.8% margin, positive NaN/8 quarters
FCF TTM $11.8B. FCF margin 2.8%, Top 50%. OCF/Net income 3.0x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 2.8% | Warning | Thin cash margins |
| Free Cash Flow (TTM) | $11.8B | Good | Positive cash generation |
| OCF/Net Income | 3.0x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: CVS HEALTH Corp at 0.8x leverage
Debt/Equity 0.8x. Total debt $61.4B, cash & investments $14.0B. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.8x | Adequate | Moderate leverage |
| Net Cash Position | $-47.5B | Warning | Net debt position |
Valuation: CVS HEALTH Corp trades at 26.9x earnings
P/E 26.9x. EV/Sales 0.4x. FCF yield 8.9%. Dividend yield 2.6%. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| P/E Ratio | 26.9x | Adequate | Premium valuation |
| EV/Sales | 0.4x | Excellent | Attractive revenue multiple |
| FCF Yield | 8.9% | Excellent | Attractive cash return |
| Dividend Yield | 2.6% | Adequate | Growth focus over income |
Capital Allocation: CVS HEALTH Corp returns 2.6% shareholder yield
Total shareholder yield 2.6% (div 2.6%). Capital returned $3.4B TTM. Source: 10-Q filed 2025-10-29.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 2.6% | Adequate | Dividend + buyback yield combined |
| Total Capital Returned (TTM) | $3.4B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.0% | Bottom 50% | 0.7x below |
| Free Cash Flow Margin | 2.8% | Top 50% | 1.1x above |
| Gross Margin | 44.5% | Top 50% | 1.2x above |
| Operating Margin | 2.0% | Bottom 50% | 0.5x below |
| Return on Equity (ROE) | 6.4% | Bottom 50% | 0.5x below |
| P/E Ratio | 26.9x | N/A | - |
Financial Scorecard
| Metric | CVS | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 5.0% | Warning | Bottom 50% of sector (median: 7.1%) |
| Free Cash Flow Margin | 2.8% | Warning | Top 50% of sector (median: 2.5%) |
| Gross Margin | 44.5% | Good | Top 50% of sector (median: 38.5%) |
| Debt to Equity Ratio | 77.0% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 26.9x | Adequate | Growth premium |
| Free Cash Flow Yield | 8.9% | Excellent | High cash return |
Frequently Asked Questions
Q: What is CVS HEALTH Corp's Return on Invested Capital (ROIC)?
CVS HEALTH Corp (CVS) has a trailing twelve-month Return on Invested Capital (ROIC) of 5.0%. Sector median 7.1%. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's Free Cash Flow Margin?
CVS HEALTH Corp (CVS) has a free cash flow margin of 2.8%, generating $11.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's P/E ratio and how does it compare to peers?
CVS HEALTH Corp (CVS) trades at a P/E ratio of 26.9x, which is above the sector median of N/A. EV/Sales 0.4x. FCF yield 8.9%. Source: 10-Q filed 2025-10-29.
Q: Does CVS HEALTH Corp pay a dividend?
CVS HEALTH Corp (CVS) currently pays a dividend yield of 2.6%. Total shareholder yield (dividend + buybacks) 2.6%. Source: 10-Q filed 2025-10-29.
Q: How much debt does CVS HEALTH Corp have?
CVS HEALTH Corp (CVS) has a debt-to-equity ratio of 0.8x with total debt of $61.4 billion. Net debt $47.5 billion. Source: 10-Q filed 2025-10-29.
Q: What is CVS HEALTH Corp's revenue and earnings growth?
CVS HEALTH Corp (CVS) grew revenue by 7.4% year-over-year. EPS +6.5% YoY. Source: 10-Q filed 2025-10-29.
Q: How does CVS HEALTH Corp compare to competitors in Consumer Discretionary?
Compared to other companies in Consumer Discretionary, CVS HEALTH Corp (CVS) shows: ROIC 5.0%, sector median 7.1% (Bottom 50%). FCF margin 2.8%, sector median 2.5% (Top 50%). Gross margin 44.5%, 6.0pp above sector median. These rankings are based on MetricDuck's analysis of all Consumer Discretionary companies with available SEC filings.
Q: What warning signs should I watch for with CVS HEALTH Corp?
Quantitative warning flags for CVS HEALTH Corp (CVS): 1) FCF margin 2.8% (below 5%). Source: 10-Q filed 2025-10-29.
Data Source: Data sourced from 10-Q filed 2025-10-29. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.